LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Suchergebnis

Treffer 1 - 6 von insgesamt 6

Suchoptionen

  1. Artikel ; Online: Preliminary outcome of Chelidonium majus (greater celandine) for COVID-19.

    Gardin, Nilo E / Braga, Anne Jacqueline

    Phytotherapy research : PTR

    2023  Band 38, Heft 2, Seite(n) 463

    Mesh-Begriff(e) Humans ; Chelidonium majus ; COVID-19 ; Chelidonium
    Sprache Englisch
    Erscheinungsdatum 2023-02-16
    Erscheinungsland England
    Dokumenttyp Letter
    ZDB-ID 639136-9
    ISSN 1099-1573 ; 0951-418X
    ISSN (online) 1099-1573
    ISSN 0951-418X
    DOI 10.1002/ptr.7776
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.B 3092: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  2. Artikel: Leserbrief. Outcome of Chelidonium majus (greater celandine) for COVID-19

    Gardin, Nilo E. / Braga, Anne Jacqueline

    Der Merkurstab

    2023  Band 76, Heft 1, Seite(n) 53

    Sprache Deutsch
    Dokumenttyp Artikel
    ZDB-ID 392536-5
    ISSN 0935-798X
    Datenquelle Current Contents Medizin

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 4326: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  3. Artikel ; Online: Greater celandine (Chelidonium majus L.) for COVID-19: A twenty-case series.

    Gardin, Nilo E / Braga, Anne Jacqueline

    Phytotherapy research : PTR

    2021  Band 35, Heft 7, Seite(n) 3792–3798

    Abstract: In December 2019, an outbreak of coronavirus disease 2019 (COVID-19) occurred in Wuhan, China, with a rapid increase in cases worldwide. Until now, among several drugs tested, none demonstrated sufficient efficacy for its etiological treatment. Greater ... ...

    Abstract In December 2019, an outbreak of coronavirus disease 2019 (COVID-19) occurred in Wuhan, China, with a rapid increase in cases worldwide. Until now, among several drugs tested, none demonstrated sufficient efficacy for its etiological treatment. Greater celandine (Chelidonium majus L.) is a well-known medicinal plant, traditionally indicated for digestive disorders and topically to remove warts. This study, performed at private offices in São Paulo and Aracaju (Brazil), describes 20 consecutive COVID-19 outpatients treated with greater celandine and their clinical evolution. The patients, aged 14-71 years (median of 41 years), were treated with Chelidonium majus 10% mother tincture, 20-30 drops three times a day for 3-12 days (median of 5 days). Clinical features were assessed during the treatment and at least until 1 week after its end. These cases were considered mild, as most COVID-19 cases. The symptoms were mainly fever, fatigue, cough, sore throat, coryza, anosmia, ageusia, and headache. Ten patients had comorbidities, such as hypertension, diabetes, and overweight. Complete or almost complete clinical improvement occurred within 1-9 days of treatment (median of 3 days). There were no adverse events. This casuistry, although small, may inspire other researchers to continue investigating Chelidonium majus as a healing treatment for COVID-19.
    Mesh-Begriff(e) Adolescent ; Adult ; Aged ; Brazil ; COVID-19/drug therapy ; Chelidonium/chemistry ; Diabetes Mellitus, Type 2 ; Female ; Humans ; Male ; Middle Aged ; Plant Preparations/therapeutic use ; Plants, Medicinal/chemistry ; Young Adult
    Chemische Substanzen Plant Preparations
    Sprache Englisch
    Erscheinungsdatum 2021-03-28
    Erscheinungsland England
    Dokumenttyp Journal Article
    ZDB-ID 639136-9
    ISSN 1099-1573 ; 0951-418X
    ISSN (online) 1099-1573
    ISSN 0951-418X
    DOI 10.1002/ptr.7085
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.B 3092: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  4. Artikel: Chelidonium majus and the image of COVID-19

    Gardin, Nilo E. / Grines, Sergio A. / Braga, Anne Jacqueline

    Der Merkurstab

    2021  Band 74, Heft 5, Seite(n) 404

    Sprache Deutsch
    Dokumenttyp Artikel
    ZDB-ID 392536-5
    ISSN 0935-798X
    Datenquelle Current Contents Medizin

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 4326: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  5. Artikel: Greater celandine (Chelidonium majus L.) for COVID‐19: A twenty‐case series

    Gardin, Nilo E. / Braga, Anne Jacqueline

    Phytotherapy research. 2021 July, v. 35, no. 7

    2021  

    Abstract: In December 2019, an outbreak of coronavirus disease 2019 (COVID‐19) occurred in Wuhan, China, with a rapid increase in cases worldwide. Until now, among several drugs tested, none demonstrated sufficient efficacy for its etiological treatment. Greater ... ...

    Abstract In December 2019, an outbreak of coronavirus disease 2019 (COVID‐19) occurred in Wuhan, China, with a rapid increase in cases worldwide. Until now, among several drugs tested, none demonstrated sufficient efficacy for its etiological treatment. Greater celandine (Chelidonium majus L.) is a well‐known medicinal plant, traditionally indicated for digestive disorders and topically to remove warts. This study, performed at private offices in São Paulo and Aracaju (Brazil), describes 20 consecutive COVID‐19 outpatients treated with greater celandine and their clinical evolution. The patients, aged 14–71 years (median of 41 years), were treated with Chelidonium majus 10% mother tincture, 20–30 drops three times a day for 3–12 days (median of 5 days). Clinical features were assessed during the treatment and at least until 1 week after its end. These cases were considered mild, as most COVID‐19 cases. The symptoms were mainly fever, fatigue, cough, sore throat, coryza, anosmia, ageusia, and headache. Ten patients had comorbidities, such as hypertension, diabetes, and overweight. Complete or almost complete clinical improvement occurred within 1–9 days of treatment (median of 3 days). There were no adverse events. This casuistry, although small, may inspire other researchers to continue investigating Chelidonium majus as a healing treatment for COVID‐19.
    Schlagwörter COVID-19 infection ; Chelidonium majus ; cough ; diabetes ; disease course ; etiology ; fever ; headache ; hypertension ; medicinal plants ; overweight ; pharyngitis ; phytotherapy ; research ; Brazil ; China
    Sprache Englisch
    Erscheinungsverlauf 2021-07
    Umfang p. 3792-3798.
    Erscheinungsort John Wiley & Sons, Ltd.
    Dokumenttyp Artikel
    Anmerkung JOURNAL ARTICLE
    ZDB-ID 639136-9
    ISSN 1099-1573 ; 0951-418X
    ISSN (online) 1099-1573
    ISSN 0951-418X
    DOI 10.1002/ptr.7085
    Datenquelle NAL Katalog (AGRICOLA)

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.B 3092: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  6. Artikel ; Online: Allogeneic hematopoietic stem cell transplantation for primary myelodysplastic syndrome Transplante alogênico de células progenitoras hematopoiéticas para síndrome mielodisplásica primária

    Carlos R. Medeiros / Nilo E. Gardin / Ricardo Pasquini

    Revista Brasileira de Hematologia e Hemoterapia, Vol 26, Iss 2, Pp 71-

    2004  Band 77

    Abstract: Characteristics and outcomes of 52 patients with myelodysplastic syndrome (MDS) who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) were analyzed. Median age was 30 years (range 2-61 years) and median time from diagnosis to allo- ... ...

    Abstract Characteristics and outcomes of 52 patients with myelodysplastic syndrome (MDS) who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) were analyzed. Median age was 30 years (range 2-61 years) and median time from diagnosis to allo-HSCT was 10 months (range 1-161 months). Thirty-six patients had advanced MDS or acute myeloid leukemia following MDS at transplant. Conditioning with busulfan and cyclophosphamide was administered to 73% of patients, and the median value of graft dose was 2.595 x 10(8) of total nucleated cells/kg. Overall survival and disease free survival at 4 years were 36% and 33%, respectively. Nineteen patients were alive, with a median follow-up of 3.8 years. Twelve patients relapsed and only one is alive, after donor lymphocyte infusion. Interval < 6 months between diagnosis and allo-HSCT decreased relapse (P = 0.01). Mortality and relapse were significantly lower among patients with less advanced disease (P = 0.03). Decreased mortality was also observed when transplant occurred after 1994, probably because more patients with less advanced disease received the procedure. Acute GVHD grades > II occurred in 19 patients. Donor type (identical related versus non-related/partially matched related) influenced the incidence of acute GVHD (P = 0.03). Eleven patients developed chronic GVHD and previous acute GVHD was a risk factor (P = 0.03). Thirty-three patients died, 22 (67%) secondary to transplant-related complications. Patients with MDS should undergo allo-HSCT earlier, mainly if they have a compatible donor and are young. Características e resultados de 52 pacientes com síndrome mielodisplásica (MDS) submetidos a transplante alogênico de células progenitoras hematopoiéticas (TCPH) foram analisados. A idade mediana foi de 30 anos (variação de 2-61 anos) e o tempo mediano entre o diagnóstico e transplante foi de dez meses (variação de 1-161 meses). Trinta e seis pacientes tinham MDS avançada ou leucemia mielóide aguda secundária a MDS ao transplante. O condicionamento com busulfano e ciclo­fosfamida foi recebido por 73% dos pacientes, e a dose celular mediana do enxerto foi de 2.56 x 10(8) células nucleadas/kg. A sobrevida global e a sobrevida livre de doença aos quatro anos foi de 36% e 33%, respectivamente. Dezenove pacientes estavam vivos, com um seguimento mediano de 3,8 anos. Doze pacientes recaíram e apenas um deles está vivo, após infusão de linfócitos do doador. Intervalo menor que 6 meses entre o diagnóstico e o transplante reduziu a ocorrência de recaída (P = 0.01). Mortalidade e recaída foram significativamente mais baixas entre os pacientes com doença menos avançada (P = 0.03). Mortalidade mais baixa também foi observada quando o transplante ocorreu após 1994, provavelmente porque mais pacientes com doença menos avançada foram transplantados. Doença do enxerto-contra-hospedeiro (DECH) aguda graus > II ocorreu em 19 pacientes, e sua incidência foi influenciada pela compatibilidade entre doador e paciente (aparentado idêntico versus não-aparentado/aparentado parcialmente compatível) (P = 0.03). Onze pacientes desenvolveram DECH crônica que teve como fator de risco DECH aguda (P = 0.03). Trinta e três pacientes morreram, sendo 22 (67%) de complicações do transplante. Estes dados sugerem que pacientes com MDS devem ser submetidos ao TCPH precocemente, principalmente se são jovens e possuem doador compatível.
    Schlagwörter Síndrome mielodisplásica ; transplante alogênico de células progenitoras hematopoiéticas ; leucemia mielóide aguda ; Myelodysplastic syndrome ; allogeneic hematopoietic stem cell transplantation ; acute myeloid leukemia ; Internal medicine ; RC31-1245 ; Medicine ; R ; DOAJ:Internal medicine ; DOAJ:Medicine (General) ; DOAJ:Health Sciences
    Sprache Englisch
    Erscheinungsdatum 2004-01-01T00:00:00Z
    Verlag Sociedade Brasileira de Hematologia e Hemoterapia
    Dokumenttyp Artikel ; Online
    Datenquelle BASE - Bielefeld Academic Search Engine (Lebenswissenschaftliche Auswahl)

    Volltext online

    Zusatzmaterialien

    Kategorien

    Fernleihe an ZB MED

    Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

Zum Seitenanfang